Waters and Andrews Alliance Sign Co-Marketing Agreement
Waters Corporation (NYSE:WAT) and Andrew Alliance today announced they have signed an agreement that will bring drug development scientists an easy-to-use, semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS. Under the co-marketing agreement, Waters will combine its existing Glycoworks™ RapiFluor-MS™ (RFMS) N-Glycan Kits with an Andrew pipetting robot that will allow laboratories to meet the demands on them for glycan profiling while improving the accuracy and precision of LC and LC-MS results.
Andrew Pipetting Robot Featured in Waters Corporation ASMS Poster- Successfully Automating Glycan Analysis
Andrew Alliance was recently featured in a poster presentation from Waters Corporation during ASMS 2017 in Indianapolis. The poster discusses and presents the successful preparation of labeled N-glycans by means of using the Andrew robot in high sensitivity LC-MS analysis. The poster concludes the Andrew Alliance pipetting system can successfully and reproducibly perform GlycoWorks with RapiFluor-MS N-Glycan rapid labeling procedures. Use of the pipetting robot allows the analyst to free time and complete two jobs in parallel while maintaining high quality and reproducible scientific results
